JMP maintains Oscient at market outperform

Oscient Pharmaceuticals Corp. was maintained by JMP Securities analyst Adam Cutler at a market outperform rating with a $3 price target. The weekly tracking of Factive prescriptions showed a total of 5,260 scripts for the week ended Nov. 4 compared with 4,527 scripts the previous week, representing 0.82% of prescriptions from the quinolone class. Prescriptions of the testosterone gel Testim were 5,181 scripts for the week ended Nov. 4 compared with 4,657 for the previous week. Shares of the Waltham, Mass.-based drug development company were up 6 cents, or 3.55%, at $1.75 on volume of 488,209 shares versus the three-month running average of 696,308 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.